2024-04-30
The concept of synthetic biology continues to gain momentum. Fushine Pharmaceuticals' microbial protein industrialization has moved from 1,000 tons to 10,000 tons.
Our reporter Cao Qi
As of the midday close on April 30, the concept of synthetic biology continued to be strong. Blue Bio and Chuan Ning Bio hit their daily limit, and Fushine Pharmaceuticals once rose by more than 12% during the session. Langkun Environment, Jiabiyu and others followed suit.
Not long ago, at the 2024 Zhongguancun Forum Annual Conference, Tan Tianwei, President of Beijing University of Chemical Technology and Academician of the Chinese Academy of Engineering, stated that the bioeconomy is expected to become the fourth industrial revolution, following the agricultural revolution, the industrial revolution, and the digital revolution. Currently, the National Development and Reform Commission (NDRC) is spearheading the joint development of a national biotechnology and biomanufacturing action plan with the Ministry of Industry and Information Technology (MIIT) and the Ministry of Science and Technology, which is expected to be released soon. "Biomanufacturing+" is a key component of this plan. According to McKinsey data, 60% of the world's products can be produced using biological methods, and by 2030 to 2040, synthetic biology could generate an estimated $2-4 trillion in direct economic impact annually.
A major area of application for synthetic biology in the food and nutrition sectors is alternative proteins. Public information indicates that Fushine Pharmaceuticals primarily specializes in the production of microbial proteins within this category. Using synthetic biology techniques, Fushine Pharmaceuticals utilizes a Fusarium chassis strain, glucose, water, and other raw materials, and produces these proteins through biomass fermentation. The company currently possesses a novel production strain, has applied for a patent, and has received a patent acceptance notice.
Reportedly, in 2023, the company reached a collaboration with a client on a microbial protein project in the field of synthetic biology, successfully achieving the industrialization of ton-scale products. Currently, the company has received orders for 1,200 tons of microbial protein products, and production and delivery are proceeding as planned. Furthermore, to meet market demand, the company has invested in a 200,000-ton annual microbial protein and resource comprehensive utilization project (Phase I). Upon completion and commissioning, the project will have an annual production capacity of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer. The project is progressing smoothly.
In addition, Fushine Pharmaceuticals has also carried out industry-university-research collaborations with the team of Academician Chen Jian from Jiangnan University and the team of Professor Tu Zongcai from Jiangxi Normal University, conducting in-depth research on microbial protein production process optimization, technological innovation, and downstream product development.
Fushine Pharmaceuticals is primarily engaged in the research, development, production, and sales of active pharmaceutical ingredients and intermediates for anti-infective drugs, with a rapidly growing lithium battery electrolyte additive business. Public information indicates that Fushine Pharmaceuticals is the only domestic supplier of sulbactam certified for the international market, one of the world's leading suppliers of tazobactam, and one of the few domestic manufacturers of carbapenem penem products with a complete industry chain from starting materials to downstream APIs.
(Editor Zhang Wei)
As of the midday close on April 30, the concept of synthetic biology continued to be strong. Blue Bio and Chuan Ning Bio hit their daily limit, and Fushine Pharmaceuticals once rose by more than 12% during the session. Langkun Environment, Jiabiyu and others followed suit.
Not long ago, at the 2024 Zhongguancun Forum Annual Conference, Tan Tianwei, President of Beijing University of Chemical Technology and Academician of the Chinese Academy of Engineering, stated that the bioeconomy is expected to become the fourth industrial revolution, following the agricultural revolution, the industrial revolution, and the digital revolution. Currently, the National Development and Reform Commission (NDRC) is spearheading the joint development of a national biotechnology and biomanufacturing action plan with the Ministry of Industry and Information Technology (MIIT) and the Ministry of Science and Technology, which is expected to be released soon. "Biomanufacturing+" is a key component of this plan. According to McKinsey data, 60% of the world's products can be produced using biological methods, and by 2030 to 2040, synthetic biology could generate an estimated $2-4 trillion in direct economic impact annually.
A major area of application for synthetic biology in the food and nutrition sectors is alternative proteins. Public information indicates that Fushine Pharmaceuticals primarily specializes in the production of microbial proteins within this category. Using synthetic biology techniques, Fushine Pharmaceuticals utilizes a Fusarium chassis strain, glucose, water, and other raw materials, and produces these proteins through biomass fermentation. The company currently possesses a novel production strain, has applied for a patent, and has received a patent acceptance notice.
Reportedly, in 2023, the company reached a collaboration with a client on a microbial protein project in the field of synthetic biology, successfully achieving the industrialization of ton-scale products. Currently, the company has received orders for 1,200 tons of microbial protein products, and production and delivery are proceeding as planned. Furthermore, to meet market demand, the company has invested in a 200,000-ton annual microbial protein and resource comprehensive utilization project (Phase I). Upon completion and commissioning, the project will have an annual production capacity of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer. The project is progressing smoothly.
In addition, Fushine Pharmaceuticals has also carried out industry-university-research collaborations with the team of Academician Chen Jian from Jiangnan University and the team of Professor Tu Zongcai from Jiangxi Normal University, conducting in-depth research on microbial protein production process optimization, technological innovation, and downstream product development.
Fushine Pharmaceuticals is primarily engaged in the research, development, production, and sales of active pharmaceutical ingredients and intermediates for anti-infective drugs, with a rapidly growing lithium battery electrolyte additive business. Public information indicates that Fushine Pharmaceuticals is the only domestic supplier of sulbactam certified for the international market, one of the world's leading suppliers of tazobactam, and one of the few domestic manufacturers of carbapenem penem products with a complete industry chain from starting materials to downstream APIs.
(Editor Zhang Wei)
